Business Context and Reporting Period
This Form 8-K Current Report was filed by Cartesian Therapeutics, Inc. on April 29, 2025. The filing discloses a significant executive transition involving the departure of the Company's Chief Technology Officer, Dr. Metin Kurtoglu, effective May 1, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and separation terms.
Material Changes and Executive Transition
- Departure: Dr. Metin Kurtoglu's employment as Chief Technology Officer ends on May 1, 2025.
- Consulting Role: Dr. Kurtoglu will transition to a consultant role from May 1, 2025, through April 30, 2026.
- Severance Package: The separation agreement includes 12 months of salary, eligibility for a pro-rated bonus, and accelerated vesting of equity awards granted on January 2, 2024.
- Release: Dr. Kurtoglu has agreed to release the Company from claims arising up to April 29, 2025, in consideration for the severance benefits.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the execution of the separation and consulting agreements to facilitate the orderly transition of the CTO role.
Investor Verification Checklist
- Verify the specific dollar value of the 12-month salary and pro-rated bonus in the original employment agreement dated March 28, 2024.
- Confirm the number of equity awards granted on January 2, 2024, that are subject to accelerated vesting.
- Review the Company's succession plan for the Chief Technology Officer role following Dr. Kurtoglu's departure.
- Check for any subsequent filings regarding the appointment of a new CTO or interim leadership.